Last edition
News about
Novo Nordisk to Acquire Akero Therapeutics Alongside Promising MASH Therapy Efruxifermin
Danish pharma giant Novo Nordisk has signed a definitive agreement to acquire Akero Therapeutics, a San Francisco-based clinical-stage biopharmaceutical company focused on developing innovative therapies for serious metabolic diseases.
KLIFO Expands Manufacturing Capacity with New Authorised Clinical Supply Facility in Copenhagen
KLIFO, a leading integrated drug development and clinical supply services provider with over 30 years of expertise, has received official manufacturing and importation authorisation from the Danish Medicines Agency for its new 65,000 sq ft Abildager facility in Copenhagen.
Natco Wins Patent Battle, Cleared to Launch Generic Risdiplam for SMA in India
Natco Pharma has won a significant legal victory in India, enabling it to launch a generic version of risdiplam, a treatment for spinal muscular atrophy (SMA). In a ruling by an appellate bench of the Delhi High Court, the court dismissed a plea by Roche seeking to block Natco’s launch, thereby allowing the Indian company to proceed with its version.
Zydus Pharmaceuticals (USA) Inc., a subsidiary of Ahmedabad-based Zydus Lifesciences, has initiated a voluntary recall of 8,784 bottles of its liver infection treatment, Entecavir, from the U.S. market.
New manufacturing facility to be located near Charlottesville, in Albemarle County, Virginia will develop and manufacture a broader range of medicines including weight management, metabolic and cancer technologies.<br />
Jubilant HollisterStier LLC (JHS) — a wholly owned subsidiary of Jubilant Pharmova and a leading North American contract manufacturer specialising in sterile injectables — has launched a new Sterile Fill & Finish line, its third at the Spokane manufacturing facility in Washington, USA.
Thermo Fisher Launches Molecular Microscope to Assess Lung Transplant Rejection
Thermo Fisher’s new Molecular Microscope Diagnostic System for Lung (MMDx Lung) leverages the power of Machine Learning (ML) to profile gene expression data from lung biopsies, comparing each new sample to a reference set of over 896 lung biopsies.
Jascayd is the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication. This represents a novel mechanism of action that exerts both antifibrotic and immunomodulatory effects, thereby slowing the decline in lung function in IPF patients.
XenoTherapeutics Completes Takeover of Canada's ESSA Pharma
Canada-based ESSA Pharma has announced the completion of its acquisition by XenoTherapeutics, a US-based research foundation focused on advancing xenotransplantation therapies.
By deploying the ExellenS framework across its manufacturing network—with standardised designs, unified processes, and advanced digital integration—Samsung Biologics ensures plant equivalency, operational speed, and seamless manufacturing continuity.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy